☆ 4.6 Article

BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac

VIRUSES-BASEL (2023)

Related references

Note: Only part of the references are listed.

Article Immunology

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters

Maria Rescigno et al.

Summary: This study compared the B-cell, T-cell, and neutralizing antibody response to WT and Omicron BA.2 SARS-CoV-2 virus in patients with hematological malignancies, solid tumors, and immune-rheumatological diseases after the fourth dose of mRNA COVID-19 vaccine. The T-cell response was similarly boosted by the fourth dose across different subgroups, while the antibody response was improved only in patients not receiving B-cell targeted therapies. However, a small percentage of patients did not have neutralizing antibodies to either virus variants, making them vulnerable to SARS-CoV-2 infection. The increment of neutralizing antibodies was similar towards Omicron BA.2 and WT virus after the third or fourth dose of vaccine. Additional booster doses are recommended for frail patients to enhance the development of a B-cell response against Omicron and/or to enhance the T-cell response in patients treated with anti-CD20.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

Eddy Perez-Then et al.

Summary: The study found that a BNT162b2 mRNA vaccine booster can enhance neutralizing antibodies against the Omicron variant in individuals who received two doses of the CoronaVac vaccine, but antibody titers remain lower compared to the ancestral virus and the Delta variant.

NATURE MEDICINE (2022)

Add to Collection

Article Allergy

Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study

Zeynep Ece Kuloglu et al.

Summary: This study aimed to investigate the effects of BNT162b2 (BNT) and CoronaVac (CV) boosters on the immune response of individuals who had received two doses of CV vaccination. The results showed that the neutralizing antibody levels were higher after 3 months of BNT booster compared to CV booster.

ALLERGY (2022)

Add to Collection

Article Surgery

Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine

Deepali Kumar et al.

Summary: The Omicron variant of the SARS-CoV-2 virus has become the dominant circulating strain globally, and three doses of mRNA COVID-19 vaccine are recommended for transplant recipients. However, there is limited research on the immunogenicity of mRNA vaccines specifically against the Omicron variant. This study analyzed the neutralization effects of Omicron in transplant recipients who received three doses of mRNA-1273 vaccine, and the results showed poor neutralizing responses against the Omicron variant in these patients.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Letter Oncology

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients

Muhammad Bilal Abid et al.

CANCER CELL (2022)

Add to Collection

Article Immunology

mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients

Jennie H. Kwon et al.

Summary: The effectiveness of COVID-19 mRNA vaccines in preventing COVID-19 hospitalization is lower for solid organ transplant (SOT) recipients compared to immunocompetent individuals and those with other immunocompromising conditions. Among SOT recipients, receiving 3 doses of an mRNA vaccine provides significantly greater protection than receiving 2 doses.

JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Letter Immunology

Clinical Impact, Reactogenicity, and Immunogenicity After the First CoronaVac Dose in Kidney Transplant Recipients

Jose Medina-Pestana et al.

TRANSPLANTATION (2022)

Add to Collection

Editorial Material Respiratory System

COVID-19 vaccine-induced immunity: Head-to-head comparison of mRNA (BNT162b2) versus inactivated (CoronaVac) vaccines

Benjamin Kagina et al.

RESPIROLOGY (2022)

Add to Collection

Letter Oncology

Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients

Xi Wu et al.

Summary: Recipients after HSCT or CAR-T therapy are at increased risk for unfavorable outcomes after SARS-CoV-2 infection. The immune response to COVID-19 vaccines is attenuated in these recipients, with time interval between transplant and vaccination, immunosuppressive therapy, and lymphocyte counts significantly affecting the humoral response in HSCT recipients. Seroconversion is higher in BCMA-based CAR-T patients compared to CD19-based CAR-T patients. An adapted vaccination strategy and further research on booster dose and cellular response are warranted for HSCT and CAR-T recipients.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Article Virology

Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment

Suresh Kumar et al.

Summary: This study used computational tools to evaluate the infectivity, transmission, and pathogenicity of the Omicron variant and its sub-variants. The research found that the Omicron and sub-variants have multiple mutations in the receptor-binding domain, increasing their affinity for human ACE2 and potential for transmission. However, mutations in the spike protein's N-terminal domain may result in less impact on the lower respiratory tract. Some mutations in the sub-variants of Omicron seemed to restore the binding effectiveness to ACE2.

JOURNAL OF MEDICAL VIROLOGY (2022)

Add to Collection

Article Immunology

Immunogenicity After a Heterologous BNT262b2 Versus Homologous Booster in Kidney Transplant Recipients Receiving 2 Doses of CoronaVac Vaccine: A Prospective Cohort Study

Jose Medina-Pestana et al.

Summary: In kidney transplant recipients who have received an adequate dose of the CoronaVac vaccine, a third dose with an mRNA vaccine resulted in a higher seroconversion rate and antibody titers compared to a third dose of the same vaccine. However, both boosters achieved equivalent seroprevalence for neutralizing antibodies. The high proportion of seronegative patients indicates the need for alternative protection strategies.

TRANSPLANTATION (2022)

Add to Collection

Article Oncology

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

Lorenzo Canti et al.

Summary: Response to SARS-CoV-2 mRNA vaccination in allogeneic hematopoietic stem cell transplantation recipients is influenced by chronic GVHD and rituximab therapy. Immunological markers could assist in identifying allo-HCT patients at risk of poor antibody response to mRNA vaccination.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang et al.

Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

Peter J. Embi et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Ilies Benotmane et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Mine Durusu Tanriover et al.

Summary: The study presented the interim efficacy and safety results of the CoronaVac vaccine in a phase 3 clinical trial in Turkey, demonstrating high efficacy against PCR-confirmed symptomatic COVID-19 with good safety and tolerability profile. Results showed significant differences in the frequency of any adverse events between the vaccine and placebo groups, indicating excellent protective effects of the vaccine.

LANCET (2021)

Add to Collection

Letter Immunology

Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients

Caroline X. Qin et al.

TRANSPLANTATION (2021)

Add to Collection

Article Oncology

Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients

Martina Chiarucci et al.

Summary: The efficacy of Covid-19 vaccine in HSCT recipients remains uncertain. This study showed that prior Rituximab in autologous HSCT and cyclosporine administration in allogeneic HSCT negatively impacted antibody response. Additionally, increased numbers of CD19+ B lymphocytes and CD56+ natural killer cells correlated significantly with antibody response.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study

Galia Rahav et al.

Summary: The antibody response to the Pfizer-BioNTech vaccine varied significantly among different immunocompromised patients, suggesting the need for individual recommendations based on specific immunosuppression states.

ECLINICALMEDICINE (2021)

Add to Collection

© Peeref 2019-2024. All rights reserved.